Medical technology leaders BD (Becton, Dickinson and Company) and Ypsomed have expanded their ongoing collaboration by introducing a new 5.5mL version of the BD Neopak XtraFlow glass prefillable syringe. This variant is engineered for full compatibility with Ypsomed’s YpsoMate 5.5 autoinjector platform.
Technical Enhancements for Complex Biologics Large-volume subcutaneous injections (typically exceeding 1mL) often present challenges due to high drug viscosity and extended injection times. The new syringe addresses these issues through specific design updates:
-
Cannula Design: Featuring a shorter 8mm needle and thinner wall cannulas to optimize medication flow.
-
Performance: These enhancements are intended to reduce injection duration and facilitate the delivery of high-viscosity biopharmaceuticals used in oncology and autoimmune treatments.
Empowering Patient Self-Administration By integrating BD’s drug delivery expertise with Ypsomed’s autoinjector leadership, the partnership aims to simplify the self-injection process for patients managing chronic conditions.
-
The YpsoMate 5.5 platform utilizes an ergonomic, two-step activation process with clear feedback mechanisms to bolster patient confidence during at-home use.
-
This development represents a strategic expansion of the delivery design space, accommodating the increasing demand for high-dose, high-volume subcutaneous therapies.